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Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, 
Bernard GR: A randomized, controlled trial of furosemide 
with or without albumin in hypoproteinemic patients with 
acute lung injury. Crit Care Med 2005, 33:1681-1687 [1]. 
Background 
Hypoproteinemia is a common condition in critically ill 
patients, associated with the development of acute lung 
injury and acute respiratory distress syndrome and 
subsequent worse clinical outcomes. Albumin with 
furosemide benefits lung physiology in hypoproteinemic 
patients with acute lung injury/acute respiratory distress 
syndrome, but the independent pharmacologic effects of 
these drugs are unknown.  
Methods 
Objective: To determine the independent pharmacologic 
effects of albumin and furosemide in hypoproteinemic 
patients with acute lung injury/acute respiratory distress 
syndrome. 
Design: Randomized, double-blinded, placebo-controlled 
multicentered trial. 
Setting: Eleven medical, surgical, and trauma intensive 
care units including 190 beds within two university hospital 
systems. 
Subjects: Forty mechanically ventilated patients with acute 
lung injury/acute respiratory distress syndrome, whose 
serum total protein concentrations were <6.0 g/dL were 
included. Patients were excluded for hemodynamic 
instability or significant renal or hepatic failure. 
Intervention: Subjects were equally randomly allocated to 
receive furosemide with albumin or furosemide with placebo 
for 72 hrs, titrated to fluid loss and normalization of serum 
total protein concentration.  
Outcomes: The primary outcome was change in 
oxygenation from baseline to day 1, with secondary 
physiologic and clinical outcomes. 
Results: There were no differences in baseline 
characteristics of the subjects in relation to group 
assignment. Albumin-treated patients had greater increases 
in oxygenation (mean change in Pao2/Fio2: +43 vs. -24 mm 
Hg at 24 hrs and +49 vs. -13 mm Hg at day 3), serum total 
protein (1.5 vs. 0.5 g/dL at day 3), and net fluid loss (-5480 
vs. -1490 mL at day 3) throughout the study period (all p < 
.05). Fluid bolus administration to control patients reduced 
net negative fluid balance; control patients more frequently 
developed hypotension and had fewer shock-free days, 
which translated to differences in organ failure at study end. 
Apart from more frequent hypotension in the control group, 
there were no adverse events. There were seven deaths in 
the treatment group and nine in the control group (35% vs. 
45% mortality rate; p = .52). 
Conclusion 
The addition of albumin to furosemide therapy in 
hypoproteinemic patients with acute lung injury/acute 
respiratory distress syndrome significantly improves 
oxygenation, with greater net negative fluid balance and 
better maintenance of hemodynamic stability. Additional 
randomized clinical trials are necessary to examine 
mechanisms and determine the effect on important clinical 
outcomes, such as the duration of mechanical ventilation. 
Commentary 
Acute lung injury (ALI) and acute respiratory distress 
syndrome (ARDS) are common, deadly, and costly [2]. The 
appropriate management of fluids and the use of colloid 
therapy in these patients have been debated for decades 
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and remain controversial. Hypoproteinemia, as previously 
shown by Martin and colleagues, is a strong independent 
predictor of development of ARDS and mortality in patients 
with sepsis [3]. In a small (n=37) randomized pilot study in 
hypoproteinemic ALI patients, those who received albumin 
plus furosemide had improved oxygenation, greater weight 
loss, and shorter duration of mechanical ventilation and ICU 
length of stay compared to those who received placebo [4]. 
Because both agents were given together in the intervention 
arm, it was not possible to distinguish which therapy, 
albumin, furosemide, or the combination, was responsible 
for the observed benefit.  
The current study by Martin and colleagues was conducted 
to evaluate the independent effect of these therapeutic 
agents in hypoproteinemic ALI patients [1]. Subjects (n=40) 
were randomized to receive furosemide with or without 
albumin (25g of 25% human serum albumin every 8 hours) 
for 72 hrs, titrated to fluid loss and normalization of serum 
total protein concentration. Hypoproteinemia was defined as 
serum total protein <6.0 g/dL. Subjects with hemodynamic 
instability or requiring vasopressors were excluded, as were 
those with significant renal or hepatic disease. Enrollment 
occurred a median of 3 days after subjects met international 
consensus conference criteria for ALI. The authors found 
that the addition of albumin to furosemide significantly 
improved oxygenation, with greater net negative fluid 
balance and better maintenance of hemodynamic stability. 
Hospital mortality was lower in the albumin/furosemide 
group, but this difference was not statistically significant 
(35% vs. 45%, p=0.52). The authors concluded that 
additional (i.e., larger) randomized trials would be necessary 
to determine if this treatment strategy improves clinical 
outcomes, such as duration of mechanical ventilation or 
mortality. 
This was a well-conducted study with a number of 
strengths. Despite the study’s small size, randomization 
succeeding in balancing key baseline characteristics across 
treatment groups. Investigators went to great lengths to 
ensure blinding. Albumin was camouflaged in sterile plastic 
containers and infused in opaque tubing to prevent it being 
distinguished from the placebo (0.9 % sodium chloride 
solution). No patients were lost to follow-up and compliance 
with the study protocol was achieved in 99% of study drug 
administrations. 
Because of its size, this study was not powered on clinical 
endpoints, such as duration of mechanical ventilation or 
mortality, and instead focused on surrogate endpoints, such 
as improvement in oxygenation. Though improvement in 
oxygenation is certainly desirable, we know from other 
studies that this may not translate into improved clinical 
outcomes, as was the case with inhaled nitric oxide in ALI. 
In fact, as pointed out by in the accompanying editorial, the 
only therapy that has been shown improve survival in ALI 
(low tidal volume ventilation) actually led to an initial 
reduction in oxygenation [6]. 
Though published in late 2005, the findings of this study are 
particularly noteworthy in light of the ARDS Network FACTT 
trial, in which two ALI fluid-management strategies, fluid 
liberal versus fluid conservative, were compared [7] starting 
an average of 24 hours after subjects met ALI criteria. In 
FACTT, subjects in the fluid conservative group had greater 
net fluid loss. As in the albumin/furosemide trial, this greater 
net fluid loss translated into improved lung function. In the 
FACTT trial, this also led to shortened duration of 
mechanical ventilation and ICU stay without increasing 
nonpulmonary-organ failures. Like the albumin/furosemide 
trial, the improvement in lung function in the FACTT trial 
was not accompanied by a statistically significant mortality 
reduction, though 60-day mortality was slightly less in the 
fluid conservative group (25.5% vs. 28.4%, p=0.30).  
Based on the results of these two studies, it would seem 
that ALI patients should be “run a bit on the dry side,” which 
on the surface might be seen to contradict the findings of 
Rivers and colleagues [8]. However, it is important to 
remember that in the Rivers study, early goal-directed 
resuscitation of septic shock (with or without ALI/ARDS) 
occurred in the first six hours after presentation to the 
emergency department, well before the FACTT trial and 
albumin/furosemide trial interventions were initiated (1 day 
and 3 days after meeting ALI criteria, respectively). While 
differences in patient populations (severe sepsis vs. 
ALI/ARDS) and interventions preclude drawing firm 
conclusions from the combined findings of these three trials, 
it seems reasonable to conclude that the exact approach to 
fluid management in ALI depends on timing. Early on in the 
acute resuscitative phase, additional fluid may be beneficial. 
Yet, once the patient is fluid resuscitated, a more 
conservative approach to fluid management may be in 
order. This “ebb and flow” hypothesis, which is well-
described in the editorial accompanying the FACTT trial 
report [9], has face-validity but remains untested. 
Recommendation 
Because of the limited size of the Martin study and its use of 
surrogate endpoints, we cannot currently recommend 
routine use of albumin and furosemide in patients with ALI. 
We do, however, anxiously await the testing of this strategy 
in a much larger randomized controlled trial. 
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